ArticleJournal of Crohn's & colitis2021

Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study.

Brian Bressler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.